New progress in treatment of hormone-refractory prostate cancer
Document Type
Article
Department
Ophthalmology
Abstract
Two studies have shown that docetaxel-based regimens yield better survival, pain control, and quality of life for patients with advanced hormone-refractory prostate cancer than do mitoxantrone-based regimens.
Publication (Name of Journal)
Lancet Oncology
Recommended Citation
Ahmed, K.
(2004). New progress in treatment of hormone-refractory prostate cancer. Lancet Oncology, 5(12), 706.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/459
COinS